title: [Current situations and the future prospect of monoclonal antibody products].
abstract: Monoclonal antibody products and monoclonal antibody-based biopharmaceuticals have shown considerable effectiveness in the treatment for variety of diseases; cancer, auto-immune/auto-inflammation diseases and so on. Significant advance in monoclonal antibody products for cancer treatments was made with antibody-drug conjugates (ADC), and antibodies for blockade of immune checkpoints. Already 3 ADCs and 2 anti-immune-checkpoint antibodies products have been approved, and these monoclonal antibody-related product pipelines reach over 30. On the other hand, EU approved first monoclonal-antibody biosimilar, RemsimaTM (infliximab), suggesting that other monoclonal-antibody biosmilars will follow to the market. In this paper, several new issues about monoclonal antibody products will be discussed.
authors.forename: Teruhide
authors.initials: T
authors.lastname: Yamaguchi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D059451:Biosimilar Pharmaceuticals; D017277:Drug Approval; D055808:Drug Discovery / Q000639:trends*; D017408:Guidelines as Topic; D006801:Humans; D018796:Immunoconjugates; D000069285:Infliximab; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D059451:Biosimilar Pharmaceuticals; D018796:Immunoconjugates; D000069285:Infliximab